We also confirmed the efficacy of inhibiting DDR1/BCR signaling (using nilotinib) in combination with lapatinib on oversized multi-spheroids of COAD line HCT116 and GBM line U251 and found significant loss of spheroid viability (Supplementary Figure 7C). Here, BCR is linked to glioblastoma.